Eisai Opens Multi-million Pound High Tech Global Potent Packaging Facility for New Cancer Treatment in UK
Eisai, a leading global R&D-based pharmaceutical company, has opened a new facility at its EMEA Knowledge Centre in Hatfield, UK, to handle the packaging of its investigational compound lenvatinib, for the treatment of advanced thyroid cancer. This represents a foreign direct investment of more than £8 million into the UK by the Japanese company.
Housing innovative hybrid packaging lines at the cutting edge of technology, the facility is specifically designed to cope with highly potent, difficult-to-handle compounds. The new two storey 2900 m2 facility expands the current Hatfield site by nearly 40% and reflects Eisai’s commitment to a long-term global business structure in which the UK is a key hub. The Hatfield site hosts the company’s EMEA headquarters and serves as a global supply centre of excellence for key products.
“Pharmaceuticals manufacturing is important to our economy, with more than £22 billion worth of exports in 2013 and a positive trade balance of just over £2 billion. Eisai's investment in this new facility will help grow these figures and is another vote of confidence for the UK’s world-class life sciences sector,” commented George Freeman MP, Minister for Life Sciences.
“The Government continues in its commitment to ensure that the UK life sciences sector is innovative and flexible, through new measures announced last week such as the Innovative Medicines and MedTech Review and the latest round of Biomedical Catalyst funding. We are committed to finding new ways to improve the lives of patients and give companies the confidence to invest and create jobs in the UK,” he added.
Eisai has invested more than £150 million in the Hatfield site, representing the largest Japanese pharmaceutical investment in the UK to date. It is home to more than 500 employees, and has the capacity to produce up to 450 million tablets in 10 million packs each year. The new packaging facility will increase employment at the site by 10% and boost the revenues of local businesses and suppliers.
"We are extremely proud of this new development at our EMEA Knowledge Centre. The UK is an ideal location for advanced manufacturing. We are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy,” Haruo Naito, CEO of Eisai Co., Ltd. said.
"This new high tech facility enhances our capability as a centre of packaging excellence for our growing product range,” he added. “As we supply products to an increasing number of countries with different languages across the world, our facility needs to cope with an extremely high mix of low-volume packaging for often difficult-to-handle compounds. The new machines were tailor-made and allow for reconfiguration of every product run particular to each national market we supply. Lenvatinib will be packaged exclusively at Hatfield and eventually export to almost 200 countries, contributing positively to the UK balance of trade.”
Lenvatinib, discovered and developed by Eisai, was granted orphan drug designation for follicular and papillary thyroid cancer by the European Commission in 2013. Regulatory submissions have been made in the EU, US and Japan. The European Medicines Agency has accepted a request for accelerated approval of lenvatinib for advanced thyroid cancer. Lenvatinib also has the potential to treat other cancers.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance